Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery.
Mastering the systematic analysis of tumor tissues on a large scale has long been a technical challenge for proteomics. In 2001, reverse phase protein arrays (RPPA) were added to the repertoire of existing immunoassays, which, for the first time, allowed a profiling of minute amounts of tumor lysates even after microdissection. A characteristic feature of RPPA is its outstanding sample capacity permitting the analysis of thousands of samples in parallel as a routine task. Until today, the RPPA approach has matured to a robust and highly sensitive high-throughput platform, which is ideally suited for biomarker discovery. Concomitant with technical advancements, new bioinformatic tools were developed for data normalization and data analysis as outlined in detail in this review. Furthermore, biomarker signatures obtained by different RPPA screens were compared with another or with that obtained by other proteomic formats, if possible. Options for overcoming the downside of RPPA, which is the need to steadily validate new antibody batches, will be discussed. Finally, a debate on using RPPA to advance personalized medicine will conclude this article.
Statistical Bioinformatics, Department of Medical Statistics, University Medical Center Goettingen, Humboldtallee 32, D-37073 Goettingen, Germany. astrid.wachter@med.uni-goettingen.de.
Astrid
A
Wachter
German Cancer Research Center (DKFZ). s.bernhardt@dkfz-heidelberg.de.
Stephan
S
Bernhardt
Statistical Bioinformatics, Department of Medical Statistics, University Medical Center Goettingen, Humboldtallee 32, D-37073 Goettingen, Germany. tim.beissbarth@ams.med.uni-goettingen.de.
Tim
T
Beissbarth
German Cancer Research Center (DKFZ). u.korf@dkfz.de.
Ulrike
U
Korf
antibody; cancer; immunoassay; reverse phase protein array; reverse phase protein arrays (RPPA); signaling pathways